The TNF member LIGHT also known as TL4 or TNFSF14) can play a major role in cancer control via its two receptors; it induces tumor cell death through lymphotoxin-b receptor (LT-bR) and ligation to the herpes virus entry mediator (HVEM) amplifies the immune response. By studying the effect of LIGHT in the transcriptional profile of a lymphoid malignancy, we found that HVEM, but not LT-bR, stimulation induces a significant increase in the expression of chemokine genes such as IL-8, and an unexpected upregulation of apoptotic genes. This had functional consequences, since LIGHT, or HVEM mAb, thus far known to costimulate T-and B-cell activation, induced chronic lymphocytic leukemia cell death. Many of the mediators involved were identified here, with an apoptotic pathway as demonstrated by caspases activation, decrease in mitochondrial membrane potential, upregulation of the pro-apoptotic protein Bax, but also a role of TRAIL. Moreover, HVEM induced endogenous TNF-a production and TNF-a enhanced HVEM-mediated cell death. HVEM function was mainly dependent on LIGHT, since other ligands like HSV-glycoprotein D and B and T lymphocyte attenuator were essentially ineffective. In conclusion, we describe a novel, as yet unknown killing effect of LIGHT through HVEM on a lymphoid malignancy, and combined with induction of chemokine release this may represent an additional tool to boost cancer immunotherapy.
2502
IntroductionThe TNF and TNF receptor (TNFR) superfamilies have diverse and widespread physiological functions, including apoptosis, proliferation, differentiation, and immune system regulation. TNFR are schematically classified into two groups: those with a 80-amino acids death domain (DD) in the cytoplasmic region of the receptor, which signals cell death, and those without DD, which have been implicated in lymphoid cell proliferation and differentiation [1,2]. LIGHT also known as TL4 or TNFSF14) is a glycosylated, type II transmembrane protein of about 29 kDa, which can bind lymphotoxin-b receptor (LT-bR) and the herpes virus entry mediator (HVEM) both of which belong to the TNFR superfamily. HVEM is a type I transmembrane protein of 32 to 36 kDa, devoid of intracytoplasmic DD. To date, five ligands have been identified for HVEM. The first one is HSV glycoprotein D (HSV-gD), a structural component of the HSV envelope, essential for HSV entry into host cells [3]. Two of the ligands are members of the TNF superfamily: the trimeric lymphotoxin a (LTa3) and LIGHT [4]. Recently, it was also found that HVEM interacts with two immunoglobulin superfamily members B and T lymphocyte attenuator (BTLA) and CD160 [5][6][7]. HVEM is expressed in most immune cells such as monocytes, T and B lymphocytes, and natural killer cells whereas expression of LT-bR is restricted to stromal cells or non-lymphoid hematopoietic cells [8,9]. Functional differences between the two receptors of LIGHT have also been observed. LIGHT binding to HVEM confers mainly costimulatory effects; LIGHT has a potent, CD28-independent, co-stimulatory role in...